Skip to main content
evidena care

Basics

The endocannabinoid system explained: CB1, CB2 and what is established

The endocannabinoid system is the body's own signalling system of receptors, messengers and enzymes. What is established about it and what remains a hypothesis.

Key points

  • The endocannabinoid system consists of the body's own cannabinoids, the receptors CB1 and CB2, and enzymes that produce and break down these messengers.
  • CB1 is the most important cannabinoid receptor in the nervous system; CB2 was first described in immune cells. Both were discovered in the early 1990s.
  • What is established: THC acts mainly via these receptors. The system influences how nerve cells transmit signals and plays a role in brain development.
  • The idea of an “endocannabinoid deficiency” as the cause of migraine, fibromyalgia or irritable bowel is not proven. It is a hypothesis without formal clinical confirmation.

The endocannabinoid system is the body’s own signalling system. It consists of messengers that the body produces itself, the endocannabinoids, the receptors CB1 and CB2 to which they bind, and enzymes that produce the messengers and break them down again. It is widespread in the nervous system and influences many processes, from signal transmission between nerve cells to brain development.1

That THC acts via this system is well documented. Many claims you read online, for example about a “deficiency” as the cause of diseases, are by contrast hypotheses. This article separates the one from the other.1,9

How the endocannabinoid system was discovered

The order of the discoveries explains the name. First, the active substances of the cannabis plant were known; then researchers looked for their targets in the body.

  • 1990: a research group described the structure of a cannabinoid receptor in the brain, today called CB1.2
  • 1992: a substance produced by the body that binds to this receptor was found in the brain. It was named anandamide.4
  • 1993: a second receptor was described, first in cells of the immune system. It is called CB2.3
  • 1995: another messenger produced by the body, 2-arachidonoylglycerol (2-AG), was identified as a binding partner of the cannabinoid receptors.5

The system is therefore named after the plant because it was found through the plant. Its actual role in the body has nothing to do with cannabis.

CB1 and CB2: the cannabinoid receptors

CB1 and CB2 belong to the large family of G protein-coupled receptors. These are proteins in the cell membrane that pass a signal from outside into the interior of the cell.6

CB1 is the predominant cannabinoid receptor in the central nervous system. However, it is also found in other organs.6 CB1 explains the typical psychological effects of THC.1,2

CB2 was first detected in cells of the immune system, not in the brain.3 It is associated with immune processes, such as the migration of immune cells.7

Besides CB1 and CB2, endocannabinoids and plant cannabinoids also bind to other targets. Which of these are counted as part of the endocannabinoid system is handled differently in research.1,7

Endocannabinoids: anandamide and 2-AG

The two best-known endocannabinoids are anandamide and 2-AG. Unlike many other messengers, they are not stored in reserve. The cell produces them as needed from components of the cell membrane, and enzymes break them down again quickly.1

One special feature concerns the direction of the signal. At many synapses, endocannabinoids pass on their signal backwards: the receiving nerve cell produces them, and they act back on the sending nerve cell. There, via CB1, they dampen the release of other messengers. In this way, the system can finely regulate signal transmission.1,6

What is established about the endocannabinoid system

The following points are well documented in research:

  • Structure: the system consists of endocannabinoids, cannabinoid receptors and enzymes for production and breakdown.1
  • Signal transmission: it is a widespread regulatory system in the nervous system and plays a role in the adaptation of synapses and in brain development.1
  • THC: cannabinoid receptors are the main target of THC, the intoxicating constituent of cannabis. At CB1 and CB2, THC is a partial agonist, meaning it activates the receptors, but not to the maximum.1,7
  • Significance for the mind: a clear example comes from drug research. Rimonabant blocks CB1 and was authorised as a weight-loss medicine. In a meta-analysis of four trials with 4105 participants, people on rimonabant stopped treatment 2.5 times as often because of depressed mood as on placebo, and anxiety also led to discontinuation more often.8 This shows that intervening in CB1 can affect the mind.

How THC and CBD intervene in the endocannabinoid system

THC partly mimics endocannabinoids and activates CB1 and CB2. How strong the response is depends on the number of receptors and on the ongoing release of the body’s own cannabinoids. With repeated use, tolerance develops.7

CBD behaves differently. In cell and tissue experiments, it inhibited the effect of other substances at CB1 and CB2.7 A laboratory study described CBD as a so-called negative allosteric modulator of CB1: it binds at a different site on the receptor and thereby dampens the effect of THC and 2-AG.10 These are laboratory findings. How much of this plays a role in humans is an open question. The overview in the Basics hub explains more about the difference between the two active substances.

Because cannabinoid receptors are found in so many places, THC does not only act where an effect is desired. This contributes to side effects such as dizziness, tiredness or difficulty concentrating. More on this in the article Cannabis side effects.1,6

What is still a hypothesis: endocannabinoid deficiency and similar ideas

The best-known unproven idea is “clinical endocannabinoid deficiency”. It holds that every person has a baseline tone of endocannabinoid activity and that a deficiency in it could cause diseases such as migraine, fibromyalgia or irritable bowel syndrome.9

The author of this theory himself states that when it was formulated in 2001, it was based on indirect evidence and that objective evidence and formal clinical studies were lacking. Since then, individual findings have been added, such as altered anandamide levels in the cerebrospinal fluid of people with migraine.9 This is an indication, but not proof of a cause. There is no test or recognised diagnosis of “endocannabinoid deficiency”.

Caution is also advisable with advertising claims that a product “brings the endocannabinoid system into balance”. There is no established clinical basis for such claims. Research on the endocannabinoid system is active, and many questions about its functions, regulation and therapeutic use remain open.1,6

How it works at evidena

At evidena, the doctor decides after an assessment whether a cannabis medicine can be considered for you. A narcotics prescription must be filled within one month. The quantity prescribed generally covers one month, in justified cases at most three months. The process is described on the How it works page, and terms are explained in the glossary.

You can book an appointment at https://portal.evidena.care/appointments. We answer questions via WhatsApp or at info@evidena.care.

Conclusion

The endocannabinoid system is a well-documented regulatory system of messengers, the receptors CB1 and CB2, and enzymes. THC acts mainly via these receptors, CBD in a more complex way. The idea of an endocannabinoid deficiency as a cause of disease, by contrast, is a hypothesis for which formal clinical evidence is lacking.

Frequently asked questions

What is the endocannabinoid system?

The body's own signalling system of messengers, the endocannabinoids, their receptors CB1 and CB2, and enzymes that produce and break down the messengers.

Where are CB1 and CB2 receptors found?

CB1 mainly in the nervous system, CB2 mainly in cells of the immune system. However, both are also found in other tissues.

What are the body's own cannabinoids called?

The two best known are anandamide and 2-arachidonoylglycerol, 2-AG for short. They were described in 1992 and 1995.

Is there such a thing as endocannabinoid deficiency?

That is a hypothesis. Individual findings fit with it, but formal clinical evidence is lacking. There is no diagnosis of “endocannabinoid deficiency”.

Can the endocannabinoid system be strengthened with dietary supplements?

There is no established evidence for this. Claims such as “balancing the endocannabinoid system” usually come from advertising, not from clinical studies.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. doi:10.1016/j.bpsc.2020.07.016
  2. Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564. doi:10.1038/346561a0
  3. Munro S et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65. doi:10.1038/365061a0
  4. Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. doi:10.1126/science.1470919
  5. Mechoulam R et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83-90. doi:10.1016/0006-2952(95)00109-d
  6. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833
  7. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. doi:10.1038/sj.bjp.0707442
  8. Christensen R et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706-1713. doi:10.1016/S0140-6736(07)61721-8
  9. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-165. doi:10.1089/can.2016.0009
  10. Laprairie RB et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-4805. doi:10.1111/bph.13250

Written by evidena.care editorial team · Published 13 November 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.